Premium
Prothrombin complex concentrate for the management of severe traumatic bleeding in a patient anticoagulated with apixaban
Author(s) -
Durie R.,
Kohute M.,
Fernandez C.,
Knight M.
Publication year - 2016
Publication title -
journal of clinical pharmacy and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.622
H-Index - 73
eISSN - 1365-2710
pISSN - 0269-4727
DOI - 10.1111/jcpt.12339
Subject(s) - apixaban , medicine , prothrombin complex concentrate , bleed , vitamin k , vitamin k antagonist , refractory (planetary science) , prothrombin complex , anesthesia , hemostatics , fresh frozen plasma , surgery , intensive care medicine , rivaroxaban , warfarin , coagulation , atrial fibrillation , hemostasis , platelet , physics , astrobiology
Summary What is known and objective Given the data for four factor prothrombin complex concentrate ( PCC ) for vitamin K antagonist ( VKA ) reversal, there is great interest to determine whether PCC can improve patient outcomes in patients with bleeds associated with the newer oral anticoagulants ( NOAC ). Case description We describe the case of an adult trauma patient anticoagulated with apixaban, presenting with a severe life‐threatening bleed. PCC was administered at the maximum dose when the patient was determined to be refractory to supportive care with blood products. What is new and conclusion Despite maximal treatment efforts, haemostasis was not achieved and the patient expired.